Targeted genome editing by artificial nucleases has brought the goal of site-specific transgene integration and gene correction within the reach of gene therapy. However, its application to long-term repopulating haematopoietic stem cells (HSCs) has remained elusive. Here we show that poor permissiveness to gene transfer and limited proficiency of the homology-directed DNA repair pathway constrain gene targeting in human HSCs. By tailoring delivery platforms and culture conditions we overcame these barriers and provide stringent evidence of targeted integration in human HSCs by long-term multilineage repopulation of transplanted mice. We demonstrate the therapeutic potential of our strategy by targeting a corrective complementary DNA into the IL2RG gene of HSCs from healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1). Gene-edited HSCs sustained normal haematopoiesis and gave rise to functional lymphoid cells that possess a selective growth advantage over those carrying disruptive IL2RG mutations. These results open up new avenues for treating SCID-X1 and other diseases.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.


  1. 1.

    & Gene therapy for PIDs: progress, pitfalls and prospects. Gene 525, 174–181 (2013)

  2. 2.

    et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013)

  3. 3.

    et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322 (2010)

  4. 4.

    et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818–823 (2009)

  5. 5.

    et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013)

  6. 6.

    Ex vivo gene transfer and correction for cell-based therapies. Nature Rev. Genet. 12, 301–315 (2011)

  7. 7.

    et al. Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Science Transl. Med. 6, 227ra33 (2014)

  8. 8.

    , & Mechanisms of retroviral integration and mutagenesis. Hum. Gene Ther. 24, 119–131 (2013)

  9. 9.

    , , , & Gene therapy: therapeutic gene causing lymphoma. Nature 440, 1123 (2006)

  10. 10.

    et al. Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med. 2, 58ra84 (2010)

  11. 11.

    , , , & Genome editing with engineered zinc finger nucleases. Natl. Rev. 11, 636–646 (2010)

  12. 12.

    & TALENs: a widely applicable technology for targeted genome editing. Nature Rev. Mol. Cell Biol. 14, 49–55 (2013)

  13. 13.

    & CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnol. 32, 347–355 (2014)

  14. 14.

    et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nature Biotechnol. 25, 1298–1306 (2007)

  15. 15.

    et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646–651 (2005)

  16. 16.

    et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nature Biotechnol. 29, 816–823 (2011)

  17. 17.

    et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39, 9283–9293 (2011)

  18. 18.

    & The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179–204 (2010)

  19. 19.

    et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014)

  20. 20.

    et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotechnol. 28, 839–847 (2010)

  21. 21.

    et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Med. 18, 807–815 (2012)

  22. 22.

    et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nature Methods 8, 861–869 (2011)

  23. 23.

    et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 117, 5561–5572 (2011)

  24. 24.

    et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217–221 (2011)

  25. 25.

    , , & Hematopoiesis: a human perspective. Cell Stem Cell 10, 120–136 (2012)

  26. 26.

    et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329, 1345–1348 (2010)

  27. 27.

    et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447, 1007–1011 (2007)

  28. 28.

    et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 8, 445–458 (2011)

  29. 29.

    et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci. Transl. Med. 6, 217ra213 (2014)

  30. 30.

    et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 7, 186–197 (2010)

  31. 31.

    et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 7, 174–185 (2010)

  32. 32.

    et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53, 1696–1707 (2011)

  33. 33.

    et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nature Biotechnol. 27, 851–857 (2009)

  34. 34.

    et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nature Biotechnol. 25, 778–785 (2007)

  35. 35.

    , , , & Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens 53, 122–134 (1999)

  36. 36.

    et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood 95, 352–359 (2000)

  37. 37.

    & Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009)

  38. 38.

    et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009)

  39. 39.

    , , , & BamTools: a C++ API and toolkit for analyzing and managing BAM files. Bioinformatics 27, 1691–1692 (2011)

  40. 40.

    et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–2948 (2007)

  41. 41.

    , , & Long-term human immune system reconstitution in non-obese diabetic (NOD)-Rag (-)-γ chain (-) (NRG) mice is similar but not identical to the original stem cell donor. Clin. Exp. Immunol. 174, 402–413 (2013)

  42. 42.

    et al. A human memory T cell subset with stem cell-like properties. Nature Med. 17, 1290–1297 (2011)

  43. 43.

    et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573–584 (2013)

Download references


We thank D. Weissman for advice on mRNA production and the whole Naldini laboratory for discussion, F. Benedicenti for help with MiSeq sequencing, L. Sergi Sergi, T. Plati, V. Valtolina, B. Camisa and A. Ranghetti for technical help. SR1 was provided by T. Boitano and M. Cooke under an MTA with the Genomics Institute of the Novartis Research Foundation. This work was supported by grants to L.N. from Telethon (TIGET grant D2) EU (FP7 222878 PERSIST, FP7 601958 SUPERSIST, ERC Advanced Grant 249845 TARGETINGGENETHERAPY) and the Italian Ministry of Health.

Author information

Author notes

    • Davide Moi
    •  & Roberta Mazzieri

    Present address: The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland 4102, Australia.

    • Angelo Lombardo
    •  & Luigi Naldini

    These authors contributed equally to this work.


  1. TIGET, San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, 20132 Milan, Italy

    • Pietro Genovese
    • , Giulia Schiroli
    • , Giulia Escobar
    • , Tiziano Di Tomaso
    • , Claudia Firrito
    • , Andrea Calabria
    • , Davide Moi
    • , Roberta Mazzieri
    • , Bernhard Gentner
    • , Eugenio Montini
    • , Angelo Lombardo
    •  & Luigi Naldini
  2. Vita Salute San Raffaele University, 20132 Milan, Italy

    • Giulia Schiroli
    • , Giulia Escobar
    • , Bernhard Gentner
    • , Angelo Lombardo
    •  & Luigi Naldini
  3. Experimental Hematology Unit, San Raffaele Scientific Institute, 20132 Milan, Italy

    • Chiara Bonini
  4. Sangamo BioSciences Inc., Richmond, California 94804, USA

    • Michael C. Holmes
    •  & Philip D. Gregory
  5. Department of Immunology Erasmus MC, University Medical Center, 3015 Rotterdam, The Netherlands

    • Mirjam van der Burg


  1. Search for Pietro Genovese in:

  2. Search for Giulia Schiroli in:

  3. Search for Giulia Escobar in:

  4. Search for Tiziano Di Tomaso in:

  5. Search for Claudia Firrito in:

  6. Search for Andrea Calabria in:

  7. Search for Davide Moi in:

  8. Search for Roberta Mazzieri in:

  9. Search for Chiara Bonini in:

  10. Search for Michael C. Holmes in:

  11. Search for Philip D. Gregory in:

  12. Search for Mirjam van der Burg in:

  13. Search for Bernhard Gentner in:

  14. Search for Eugenio Montini in:

  15. Search for Angelo Lombardo in:

  16. Search for Luigi Naldini in:


P.G. designed experiments, performed research, interpreted data and wrote the manuscript. G.S. and G.E. performed research and interpreted data. T.D.T. performed mRNA production. C.F. characterized the corrective cDNA. A.C. and E.M. performed bioinformatics analysis of ZFN specificity. R.M. and D.M. developed the NSG human tumour rejection model. C.B. contributed to the T-cell studies. M.v.d.B. provided SCID-X1 patient cells. M.C.H. and P.D.G. provided ZFNs, interpreted data and edited the manuscript. B.G. set up culture conditions for HSC maintenance. A.L. and L.N. designed and supervised research, interpreted data and wrote the manuscript. L.N. coordinated the study. G.S. and G.E. contributed equally to this work. A.L. and L.N. share senior authorship.

Competing interests

M.C.H. and P.D.G. are employees of Sangamo BioSciences Inc. P.G., A.L., L.N., M.C.H. and P.D.G. filed a patent application on the protocol for targeted integration in human HSPC.

Corresponding author

Correspondence to Luigi Naldini.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Text, Supplementary Figures, Supplementary Tables and a list of primers.

About this article

Publication history







By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.